|
1
|
Youness RA, Elemam NM, Abdelhamid AM,
Mohamed AH, Elsherbiny LM, Ramzy A and Assal RA: Macrophage
migration inhibitory factor (MIF) and the tumor ecosystem: A tale
of inflammation, immune escape, and tumor growth. Front Immunol.
16(1636839)2025.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Huang Y, Chen L, Li L, Qi Y, Tong H, Wu H,
Xu J, Leng L, Cheema S, Sun G, et al: Downregulation of adipose LPL
by PAR2 contributes to the development of hypertriglyceridemia. JCI
Insight. 9(e173240)2024.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Camacho Meza G, Avalos Navarro G, De La
Cruz Mosso U, Ramírez Patiño R, Muñoz Valle JF and Bautista Herrera
LA: Macrophage migration inhibitory factor: Exploring physiological
roles and comparing health benefits against oncogenic and
autoimmune risks (review). Int J Mol Med. 56(149)2025.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Aliyarbayova A, Sultanova T, Yaqubova S,
Najafova T, Sadiqova G and Salimova A: Macrophage migration
inhibitory factor: Its multifaceted role in inflammation and immune
regulation across organ systems. Cell Physiol Biochem. 59:569–588.
2025.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Sumaiya K, Langford D, Natarajaseenivasan
K and Shanmughapriya S: Macrophage migration inhibitory factor
(MIF): A multifaceted cytokine regulated by genetic and
physiological strategies. Pharmacol Ther.
233(108024)2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Altulea A, Nehme J and Demaria M: Dual
role of MIF in aging and cellular senescence. Cytokine Growth
Factor Rev. 89:5–14. 2026.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Liu Y, Wang T, Wu R, Gao J, Cai J, Huo L,
Li X, Li J, Wang J, Wang Z, et al: Single-cell transcriptome atlas
and genome-wide Mendelian randomization reveal chemokine
involvement in diverse immune cells in type 2 diabetes. Int J Obes
(Lond). 49:2213–2228. 2025.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kardinal R and Wachten D: Macrophages in
metaflammation-fueling chronic inflammation in metabolic disease.
Pflugers Arch. 478(10)2025.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Pawelec G, Goldeck D and Derhovanessian E:
Inflammation, ageing and chronic disease. Curr Opin Immunol.
29:23–28. 2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Crasan IM, Tanase M, Delia CE,
Gradisteanu-Pircalabioru G, Cimpean A and Ionica E:
Metaflammation's role in systemic dysfunction in obesity: A
comprehensive review. Int J Mol Sci. 26(10445)2025.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Rubino F, Cummings DE, Eckel RH, Cohen RV,
Wilding JPH, Brown WA, Stanford FC, Batterham RL, Farooqi IS,
Farpour-Lambert NJ, et al: Definition and diagnostic criteria of
clinical obesity. Lancet Diabetes Endocrinol. 13:221–262.
2025.PubMed/NCBI View Article : Google Scholar
|
|
12
|
NIH: Overweight and Obesity: Obesity and
Women's Health. National Heart, Lung and Blood Institute. Available
from: https://www.nhlbi.nih.gov/health/overweight-and-obesity/women.
Accessed at December 16, 2025.
|
|
13
|
Chen Y, Wang R, Zhang N and Xu L: The dual
burden of obesity: Decoding metabolism and female reproductive
endocrinology. Front Physiol. 16(1627607)2025.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Weiskirchen R and Lonardo A: Semaglutide
from bench to bedside: The experimental journey towards a
transformative therapy for diabetes, obesity and metabolic liver
disorders. Med Sci (Basel). 13(265)2025.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Gemici AA, Bayram E, Hocaoglu E and Inci
E: Comparison of breast density assessments according to BI-RADS 4
and 5th editions and experience level. Acta Radiol Open.
9(2058460120937381)2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Newell MS, Destounis SV, Leung JWT,
DeMartini WB, Lee CH and Eby PR: ACR BI-RADS® v2025
Manual. American College of Radiology; Reston, VA, USA, 2025.
|
|
17
|
Magny SJ, Shikhman R and Keppke AL: Breast
Imaging Reporting and Data System. In: StatPearls. StatPearls
Publishing, Treasure Island, FL, 2026.
|
|
18
|
Zhang Z, Ray RM, An R, Klonoff-Cohen HS
and Thomas DB: Mammographic density as a mediator for breast cancer
risk: Pooled analysis of four population-based case-control studies
on women with screening mammograms under 50. Cancer Epidemiol
Biomarkers Prev. 35:465–474. 2026.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Morrison MC and Kleemann R: Role of
macrophage migration inhibitory factor in obesity, insulin
resistance, type 2 diabetes, and associated hepatic co-morbidities:
A comprehensive review of human and rodent studies. Front Immunol.
6(308)2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Mora Barthelmess R, Stijlemans B and Van
Ginderachter JA: Hallmarks of cancer affected by the MIF cytokine
family. Cancers (Basel). 15(395)2023.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Bucala R and Donnelly SC: Macrophage
migration inhibitory factor: A probable link between inflammation
and cancer. Immunity. 26:281–285. 2007.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Alvehus M, Burén J, Sjöström M, Goedecke J
and Olsson T: The human visceral fat depot has a unique
inflammatory profile. Obesity (Silver Spring). 18:879–883.
2010.PubMed/NCBI View Article : Google Scholar
|
|
23
|
González-Muniesa P, Marrades MP, Martínez
JA and Moreno-Aliaga MJ: Differential proinflammatory and oxidative
stress response and vulnerability to metabolic syndrome in habitual
high-fat young male consumers putatively predisposed by their
genetic background. Int J Mol Sci. 14:17238–17255. 2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Skurk T, Herder C, Kräft I,
Müller-Scholze S, Hauner H and Kolb H: Production and release of
macrophage migration inhibitory factor from human adipocytes.
Endocrinology. 146:1006–1011. 2005.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Chen L, Li L, Cui D, Huang Y, Tong H,
Zabihi H, Wang S, Qi Y, Lakowski T, Leng L, et al: Extracellular
macrophage migration inhibitory factor (MIF) downregulates adipose
hormone-sensitive lipase (HSL) and contributes to obesity. Mol
Metab. 79(101834)2024.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Lee MJ and Kim J: The pathophysiology of
visceral adipose tissues in cardiometabolic diseases. Biochem
Pharmacol. 222(116116)2024.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Khan S, Chan YT, Revelo XS and Winer DA:
The immune landscape of visceral adipose tissue during obesity and
aging. Front Endocrinol (Lausanne). 11(267)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Herder C, Klopp N, Baumert J, Müller M,
Khuseyinova N, Meisinger C, Martin S, Illig T, Koenig W and Thorand
B: Effect of macrophage migration inhibitory factor (MIF) gene
variants and MIF serum concentrations on the risk of type 2
diabetes: Results from the MONICA/KORA Augsburg Case-Cohort Study,
1984-2002. Diabetologia. 51:276–284. 2008.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kim H, Lee S, Kim HJ, Kong MH, Kim YR,
Kang SH, Lee K, Leng L, Lee B, Park CG, et al: Elevated levels of
macrophage migration inhibitory factor in women with metabolic
syndrome. Horm Metab Res. 43:642–645. 2011.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Liu T, Zhang T, Guo C, Liang X, Wang P and
Zheng B: Murine double minute 2-mediated estrogen receptor 1
degradation activates macrophage migration inhibitory factor to
promote vascular smooth muscle cell dedifferentiation and oxidative
stress during thoracic aortic aneurysm progression. Biochim Biophys
Acta Mol Cell Res. 1871(119661)2024.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Houdeau E, Moriez R, Leveque M,
Salvador-Cartier C, Waget A, Leng L, Bueno L, Bucala R and
Fioramonti J: Sex steroid regulation of macrophage migration
inhibitory factor in normal and inflamed colon in the female rat.
Gastroenterology. 132:982–993. 2007.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Mejia-Montilla J, Álvarez-Mon M,
Reyna-Villasmil E, Torres-Cepeda D, Santos-Bolívar J,
Reyna-Villasmil N, Suarez-Torres I and Bravo-Henríquez A:
Macrophage migration inhibitory factor in obese and non obese women
with polycystic ovary syndrome. Endocrinol Nutr. 62:31–37.
2015.PubMed/NCBI View Article : Google Scholar : (In English,
Spanish).
|
|
33
|
Teede HJ, Khomami MB, Morman R, Laven JSE,
Joham AE, Costello MF, Patil M, Rees DA, Berry L, Cree MG, et al:
Polyendocrine metabolic ovarian syndrome, the new name for
polycystic ovary syndrome: A multistep global consensus process.
Lancet. 407:2329–2339. 2026.PubMed/NCBI View Article : Google Scholar
|
|
34
|
He Z, Wang Y, Zhuan L, Li Y, Tang ZO, Wu Z
and Ma Y: MIF-mediated NF-κB signaling pathway regulates the
pathogenesis of polycystic ovary syndrome in rats. Cytokine.
146(155632)2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Zhou DN, Li SJ, Ding JL, Yin TL, Yang J
and Ye H: MIF May participate in pathogenesis of polycystic ovary
syndrome in rats through MAPK signalling pathway. Curr Med Sci.
38:853–860. 2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Avalos-Navarro G, Muñoz-Valle JF,
Daneri-Navarro A, Quintero-Ramos A, Franco-Topete RA, Morán-Mendoza
AJ, Oceguera-Villanueva A, Bautista-Herrera LA, Topete-Camacho A
and Del Toro-Arreola A: Circulating soluble levels of MIF in women
with breast cancer in the molecular subtypes: Relationship with
Th17 cytokine profile. Clin Exp Med. 19:385–391. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Verjans E, Noetzel E, Bektas N, Schütz AK,
Lue H, Lennartz B, Hartmann A, Dahl E and Bernhagen J: Dual role of
macrophage migration inhibitory factor (MIF) in human breast
cancer. BMC Cancer. 9(230)2009.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Fernández-Morata J, Pollán M, Fernández de
Larrea-Baz N, Pachón-Olmos V, García-Pérez J, Castelló A, Sierra
MÁ, Lucas P, Llobet R, Stradella A, et al: Mammographic density and
breast cancer pathological subtypes by menopausal status and body
mass index. Breast Cancer Res. 27(187)2025.PubMed/NCBI View Article : Google Scholar
|
|
39
|
López-Otín C, Blasco MA, Partridge L,
Serrano M and Kroemer G: Hallmarks of aging: An expanding universe.
Cell. 186:243–278. 2023.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Valdez CN, Sánchez-Zuno GA, Bucala R and
Tran TT: Macrophage migration inhibitory factor (MIF) and
D-dopachrome tautomerase (DDT): Pathways to tumorigenesis and
therapeutic opportunities. Int J Mol Sci. 25(4849)2024.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Guo S, Zhao Y, Yuan Y, Liao Y, Jiang X,
Wang L, Lu W and Shi J: Progress in the development of macrophage
migration inhibitory factor small-molecule inhibitors. Eur J Med
Chem. 286(117280)2025.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Treasure K, Harris J and Williamson G:
Exploring the anti-inflammatory activity of sulforaphane. Immunol
Cell Biol. 101:805–828. 2023.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Harris J, VanPatten S, Deen NS, Al-Abed Y
and Morand EF: Rediscovering MIF: New tricks for an old cytokine.
Trends Immunol. 40:447–462. 2019.PubMed/NCBI View Article : Google Scholar
|
